Sign In
Buy SPRO
$1.17
-0.0300 (-2.50%)
At Close: Jul 31, 2026
Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer
08:00am, Monday, 27'th Jul 2026
Dr. Zack brings more than 25 years of leadership in developing therapeutics for immune-mediated diseases Appointment strengthens Spero's clinical leadership team as the Company advances SP001, a Phase
Spero Therapeutics: 'Buy' On Utebzi Royalty Deal For Funding And SP001 In-Licensing
01:40pm, Tuesday, 14'th Jul 2026
Spero Therapeutics is initiated with a "Buy" rating, driven by its strategic pivot to immunology and strong non-dilutive financing. SPRO secured FDA approval for Utebzi and a $105M royalty deal, enabl
Spero Therapeutics Announces $105 Million Non-Recourse Non-Dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties
06:02am, Tuesday, 14'th Jul 2026
CAMBRIDGE, Mass., July 14, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immunology a
CAMBRIDGE, Mass. and SAN FRANCISCO and SUZHOU, China, July 14, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) and Innovent Biologics, Inc. (01801.HK) today announced an exclusive lic
Under the terms of the agreement, Spero will receive exclusive global rights, excluding Greater China, to develop, research, manufacture, and commercialize IBI355 (Spero R&D code: SP001) Innovent will
Avacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directors
02:00am, Wednesday, 08'th Jul 2026
LONDON and PHILADELPHIA, July 08, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activa
Spero Therapeutics: Yesterday's Selloff On Utebzi Approval Seems Bewildering
03:41pm, Thursday, 18'th Jun 2026
Spero Therapeutics, Inc. and partner GSK receive FDA approval for Utebzi, the first oral carbapenem for complicated urinary tract infections, via partnership with GSK. SPRO stands to receive milestone
GSK's Utebzi Wins FDA Nod for Complicated Urinary Tract Infections
10:01am, Thursday, 18'th Jun 2026
GSK wins FDA approval for Utebzi, the first oral carbapenem for complicated UTIs, further expanding its anti-infectives portfolio.
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
04:21pm, Wednesday, 17'th Jun 2026
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) and Spero Therapeutics (Nasdaq: SPRO) today announced that the US Food and Drug Administration (FDA) has approved Utebzi, an oral antibiotic for
Utebzi (tebipenem pivoxil) approved in the US for adults with complicated urinary tract infections (cUTIs)
12:36pm, Wednesday, 17'th Jun 2026
CAMBRIDGE, Mass., June 17, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) and GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Uteb
Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update
04:05pm, Wednesday, 13'th May 2026
New Drug Application (NDA) for tebipenem HBr for complicated urinary tract infections (cUTI), including pyelonephritis, is under review at the FDA, with PDUFA date of June 18, 2026 Spero maintains its
Spero Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 13, 2026
04:05pm, Tuesday, 05'th May 2026
CAMBRIDGE, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics , Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rare
Spero Therapeutics (NASDAQ:SPRO) versus Mereo BioPharma Group (NASDAQ:MREO) Financial Contrast
02:30am, Saturday, 28'th Mar 2026
Spero Therapeutics (NASDAQ: SPRO - Get Free Report) and Mereo BioPharma Group (NASDAQ: MREO - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the
Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update
04:05pm, Thursday, 26'th Mar 2026
CAMBRIDGE, Mass., March 26, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rar
Spero Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 26, 2026
04:05pm, Wednesday, 18'th Mar 2026
CAMBRIDGE, Mass., March 18, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on identifying and developing novel treatments for rar
